As a positive control, similar observations were made in cetuximab-resistant KRAS mutant tumors, as seen by a greater tumor volume increase observed at 3 weeks post-treatment (p < 0.001, Fig. 3e), as well as by a lower fraction of responder cases (PR, SD-PR) in the KRAS mutant-like group compared to the KRAS WT-like group (Fisher exact p < 0.0001, ORR = 2% vs. 28%, respectively, Fig. 3f). The gene discussed is KRAS; the disease is neoplasm.